{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T07:11:17Z","timestamp":1779261077730,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T00:00:00Z","timestamp":1491264000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Seoul National University Bundang Hospital Research Fund","award":["11\u20132011-035"],"award-info":[{"award-number":["11\u20132011-035"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s12185-017-2225-1","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T10:19:20Z","timestamp":1491387560000},"page":"229-239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials"],"prefix":"10.1007","volume":"106","author":[{"given":"Koung Jin","family":"Suh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Yeop","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Mee","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seonyang","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9402-6372","authenticated-orcid":false,"given":"Jeong-Ok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,4]]},"reference":[{"key":"2225_CR1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"2225_CR2","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"2225_CR3","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim D-W, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354.","journal-title":"Leukemia"},{"key":"2225_CR4","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","volume":"123","author":"NP Shah","year":"2014","unstructured":"Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Br\u00fcmmendorf TH, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014;123:2317\u201324.","journal-title":"Blood"},{"key":"2225_CR5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013;27:107\u201312.","journal-title":"Leukemia"},{"key":"2225_CR6","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3109\/10428194.2014.994205","volume":"56","author":"J Gora-Tybor","year":"2015","unstructured":"Gora-Tybor J, Medras E, Calbecka M, Kolkowska-Le\u015bniak A, Ponikowska-Szyba E, Robak T, et al. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment. Leuk Lymphoma. 2015;56:2309\u201314.","journal-title":"Leuk Lymphoma"},{"key":"2225_CR7","unstructured":"Busque L, Gratton M-O, Harnois M, et al. Real life analysis of CML management demonstrates that second-line therapy is frequently used but is prematurely discontinued for intolerance: report of the groupe Quebecois De Recherche En LMC-NMP. Haematologica. 2015;100:231."},{"key":"2225_CR8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"2225_CR9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245\u201351.","journal-title":"J Clin Epidemiol"},{"key":"2225_CR10","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041\u201351.","journal-title":"J Clin Oncol"},{"key":"2225_CR11","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054\u201361.","journal-title":"Leukemia"},{"key":"2225_CR12","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1038\/bcj.2012.30","volume":"2","author":"DJ DeAngelo","year":"2012","unstructured":"DeAngelo DJ. Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy. Blood Cancer J. 2012;2:e95.","journal-title":"Blood Cancer J"},{"key":"2225_CR13","doi-asserted-by":"crossref","first-page":"vii72","DOI":"10.1093\/annonc\/mds228","volume":"23","author":"M Baccarani","year":"2012","unstructured":"Baccarani M, Pileri S, Steegmann J-L, Muller M, Soverini S, Dreyling M, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23:vii72\u20137.","journal-title":"Ann Oncol."},{"key":"2225_CR14","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/10428191003637282","volume":"51","author":"G Rosti","year":"2010","unstructured":"Rosti G, Castagnetti F, Gugliotta G, Palandri F, Martinelli G, Baccarani M. Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a \u201chead-to-head comparison\u201d. Leuk Lymphoma. 2010;51:583\u201391.","journal-title":"Leuk Lymphoma"},{"key":"2225_CR15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2015.12.003","volume":"16","author":"K Sasaki","year":"2016","unstructured":"Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, et al. Clinical safety and efficacy of nilotinib or dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia and pre-existing liver and\/or renal dysfunction. Clin Lymphoma Myeloma Leuk. 2016;16:152\u201362.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2225_CR16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/ajh.24247","volume":"91","author":"C Gambacorti-Passerini","year":"2016","unstructured":"Gambacorti-Passerini C, Aroldi A, Cordani N, Piazza R. Chronic myeloid leukemia: second-line drugs of choice. Am J Hematol. 2016;91:67\u201375.","journal-title":"Am J Hematol"},{"key":"2225_CR17","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3109\/10428194.2015.1091929","volume":"57","author":"C Chai-Adisaksopha","year":"2016","unstructured":"Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis. Leuk Lymphoma. 2016;57:1300\u201310.","journal-title":"Leuk Lymphoma"},{"key":"2225_CR18","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","volume":"125","author":"J Wang","year":"2015","unstructured":"Wang J, Shen Z-X, Saglio G, Jin J, Huang H, Hu Y, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood. 2015;125:2771\u20138.","journal-title":"Blood"},{"key":"2225_CR19","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210\u20138.","journal-title":"J Clin Oncol"},{"key":"2225_CR20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.24734","volume":"116","author":"K Porkka","year":"2010","unstructured":"Porkka K, Khoury HJ, Pquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100\u00a0mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116:377\u201386.","journal-title":"Cancer"},{"key":"2225_CR21","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama A, Kantarjian H, O\u2019Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908\u201314.","journal-title":"J Clin Oncol"},{"key":"2225_CR22","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","volume":"125","author":"D Montani","year":"2012","unstructured":"Montani D, Bergot E, G\u00fcnther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125:2128\u201337.","journal-title":"Circulation"},{"key":"2225_CR23","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/ajh.24174","volume":"90","author":"NP Shah","year":"2015","unstructured":"Shah NP, Wallis N, Farber HW, Mauro MJ, Wolf RA, Mattei D, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015;90:1060\u20134.","journal-title":"Am J Hematol"},{"key":"2225_CR24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1183\/09031936.00154210","volume":"38","author":"D Dumitrescu","year":"2011","unstructured":"Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur Respir J. 2011;38:218\u201320.","journal-title":"Eur Respir J"},{"key":"2225_CR25","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/bmt.2008.415","volume":"43","author":"D Mattei","year":"2009","unstructured":"Mattei D, Feola M, Orzan F, Mordini N, Rapezzi D, Gallamini A. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transpl. 2009;43:967\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2225_CR26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.leukres.2008.09.026","volume":"33","author":"W Rasheed","year":"2009","unstructured":"Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res. 2009;33:861\u20134.","journal-title":"Leuk Res"},{"key":"2225_CR27","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon F-X, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381\u20138.","journal-title":"J Clin Oncol"},{"key":"2225_CR28","doi-asserted-by":"crossref","first-page":"3437\u20133437","DOI":"10.1182\/blood.V116.21.3437.3437","volume":"116","author":"A Guerin","year":"2010","unstructured":"Guerin A, Bollu V, Guo A, Griffin JD, Yu AP, Wu EQ. Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia. Blood. 2010;116:3437\u20133437.","journal-title":"Blood"},{"key":"2225_CR29","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.18553\/jmcp.2015.21.11.1088","volume":"21","author":"L Chen","year":"2015","unstructured":"Chen L, Wu EQ. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. J Manag Care Spec Pharm. 2015;21:1088.","journal-title":"J Manag Care Spec Pharm"},{"key":"2225_CR30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3111\/13696998.2015.1126285","volume":"19","author":"J Whalen","year":"2016","unstructured":"Whalen J, Stillman I, Ambavane A, Felber E, Makenbaeva D, Bolinder B. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia. J Med Econ. 2016;19:445\u201361.","journal-title":"J Med Econ"},{"key":"2225_CR31","first-page":"982395","volume":"2015","author":"U Rochau","year":"2015","unstructured":"Rochau U, Kluibenschaedl M, Stenehjem D, Kuan-Ling K, Radich J, Oderda G, et al. Effectiveness and cost-effectiveness of sequential treatment of patients with chronic myeloid leukemia in the united states: a decision analysis. Leuk Res Treat. 2015;2015:982395.","journal-title":"Leuk Res Treat"},{"key":"2225_CR32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","volume":"23","author":"F Efficace","year":"2013","unstructured":"Efficace F, Baccarani M, Breccia M, Saussele S, Abel G, Caocci G, et al. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res. 2013;23:825\u201336.","journal-title":"Qual Life Res"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-017-2225-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2225-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2225-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T23:42:43Z","timestamp":1601854963000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-017-2225-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["2225"],"URL":"https:\/\/doi.org\/10.1007\/s12185-017-2225-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,4]]}}}